Global Gastrointestinal Diseases Drug Development Market – Industry Trends and Forecast to 2030

Gastrointestinal Diseases Drug Development Market Analysis and Size

Global gastrointestinal diseases drug development market has experienced significant growth due to the increasing prevalence of GI disorders is one of the driving factors for the global gastrointestinal diseases drug development market. According to the GI Alliance data from February 2021, it is estimated that around 20 million Americans suffer from chronic digestive diseases and over 62 million Americans are diagnosed with gastrointestinal diseases annually, and the incidence of gastrointestinal disorders rises with age.

Data Bridge Market Research analyses that the global gastrointestinal diseases drug development market which was USD 37,114.12 million in 2022, is expected to reach USD 46,334.12 million by 2030, and is expected to undergo a CAGR of 3.30% during the forecast period of 2023 to 2030. “Gastroenteritis” dominates the disease type segment of the global gastrointestinal diseases drug development market due to advancements in prenatal imaging and diagnosis. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Gastrointestinal Diseases Drug Development Market Scope and Segmentation

Market Definition

Gastrointestinal diseases drug development encompasses all activities related to the research, development, testing, and commercialization of pharmaceutical products and therapies designed to diagnose, treat, or manage gastrointestinal diseases. This includes drug discovery, clinical trials, regulatory approvals, and post-market monitoring of medications targeting a wide spectrum of GI conditions, including gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), hepatitis, and more.

Global Gastrointestinal Diseases Drug Development Market Dynamics

Drivers

• High Prevalence of Gastrointestinal Disorders

Gastrointestinal disorders are among the most common health issues globally. Conditions such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and hepatitis affect millions of individuals. The rising prevalence of these disorders serves as a primary driver for drug development in the GI diseases market

• Advancements in Drug Discovery Technologies

The pharmaceutical industry has witnessed significant advancements in drug discovery technologies. Genomics, proteomics, high-throughput screening, and computational biology have revolutionized the process of identifying drug targets and designing novel therapies. These technologies enhance the precision and efficiency of drug development for GI diseases

• Growing Aging Population

The global demographic landscape is shifting, with an increasing aging population. Older adults are more susceptible to various GI conditions, including gastrointestinal cancers, diverticulitis, gallstones, and functional bowel disorders. The aging population creates a substantial market for GI drug development

Opportunities

• Biological Therapies and Targeted Treatments

Biologic therapies and targeted treatments hold significant opportunities in the GI diseases drug development market. Monoclonal antibodies, immune modulators, and cytokine inhibitors have demonstrated effectiveness in treating conditions such as Crohn's disease and ulcerative colitis

• Digital Health and Telemedicine

Digital health technologies and telemedicine platforms are transforming healthcare delivery and patient monitoring. These technologies offer opportunities to improve patient engagement, medication adherence, and real-time data collection, enhancing the effectiveness of GI treatments and clinical trials

Restraints/Challenges

• Stringent Regulatory Requirements

The pharmaceutical industry is subject to rigorous regulatory oversight. Developing drugs for GI diseases entails navigating complex regulatory pathways, adhering to stringent safety and efficacy standards, and conducting extensive clinical trials

• Drug Resistance and Long-Term Efficacy

Addressing drug resistance and ensuring the long-term efficacy of GI medications is a persistent challenge. Some GI conditions, such as hepatitis, can develop drug-resistant strains over time. Drug resistance can reduce the effectiveness of treatment and necessitate the development of alternative medications. Ensuring long-term efficacy is essential for managing chronic GI diseases

This global gastrointestinal diseases drug development market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global gastrointestinal diseases drug development market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In March 2022, AbbVie Inc. received U.S. FDA approval for its RINVOQ (upadacitinib) prescription medicine for the treatment of severe to moderate ulcerative colitis in adults. It is expected to increase the adoption of RINVOQ to treat patients who have an inadequate response to TNF blockers

Global Gastrointestinal Diseases Drug Development Market Scope

The global gastrointestinal diseases drug development market is segmented on the basis of disease type, molecular targets, marketed drugs, clinical trials, route of administration, and end-users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Type

• Gastroenteritis
• Inflammatory Bowel Disease (IBD)
• Irritable Bowel Syndrome
• Others

Molecular Targets

• Sodium Transporter NHE3 Inhibitor
• Sphinogosine-1-Phosphate Receptor Functional Antagonist
• Tumor Necrosis Factor (TNF) Blocker
• Others

Marketed Drugs

• Infliximab
• Adalimumab
• Mesalazine
• Others

Clinical Trials

• Etrolizumab
• SHP647
• ABX464
• ASP3291
• Others

Route of Administration

• Oral
• Injectable

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Gastrointestinal Diseases Drug Development Market Regional Analysis/Insights

The global gastrointestinal diseases drug development market is analysed and market size insights and trends are provided by disease type, molecular targets, marketed drugs, clinical trials, route of administration, and end-users as referenced above.

The countries covered in the global gastrointestinal diseases drug development market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the global gastrointestinal diseases drug development market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is because of the increase in the expenditure for research and development proficiencies, increasing government’s initiatives and improved health care infrastructure in various countries.

Asia-Pacific on the other hand is projected to exhibit the highest growth rate in the global gastrointestinal diseases drug development market during the forecast period of 2023 to 2030 owing to the increasing government expenditure on healthcare sector and rising technological advancements and initiatives by the government.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The global gastrointestinal diseases drug development market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global gastrointestinal diseases drug development market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global gastrointestinal diseases drug development market. The data is available for historic period 2015 to 2020.

Competitive Landscape and Global Gastrointestinal Diseases Drug Development Market Share Analysis

The global gastrointestinal diseases drug development market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to global gastrointestinal diseases drug development market.

Some of the major players operating in the global gastrointestinal diseases drug development market are:

• GSK plc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Novartis AG (Switzerland)
• Astrazeneca (U.S.)
• Pfizer Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Sanofi (U.S.)
• Amgen Inc. (U.S.)
• Daiichi Sankyo Company Limited (Japan)
• AB Sciences (France)
• Eisai Co., Ltd (Japan)
• Genentech Inc. (U.S)
• Merck & Co., Inc. (U.S.)

SKU-46330